Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung Adenocarcinoma

Lung Cancer Clinical Trial

Official title:

Investigation of the Contents and Prognostic Values of Glucose Metabolism Molecules in Patients With Lung Adenocarcinoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03641105
• Other study ID #: ZST-GLUMETA
• Status: Active, not recruiting
• Start date: January 1, 2014
• Est. completion date: March 1, 2019

Study information

• Verified date: August 2018
• Source: Shanghai Zhongshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Detect the contents of glucose metabolism molecules in the tumor and adjacent normal samples of about 100 patients with lung adenocarcinoma using mass spectroscopy. Analyze the correlation between the contents and the clinicopathological characteristics and survival.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: March 1, 2019
• Est. primary completion date: March 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Primary lung adenocarcinoma

Exclusion Criteria:

• Other tumor histories, received radiotherapy or chemotherapy before surgery, tumor or adjacent normal tissues can't be obtained, patient rejected.

Related Conditions & MeSH terms

• Adenocarcinoma
• Diagnosis
• Glycolysis
• Lung Cancer
• Survival

Intervention

Diagnostic Test:
• Diagnostic test
detect the contents of glucose metabolism molecules using mass spectrum

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease-free survival	disease-free survival	1 month
Secondary	overall survival	overall survival	1 month